Metsera Responds to Pfizer Litigation Amid Acquisition Proposal

Summary

On November 3, 2025, Metsera, Inc. issued a statement in response to litigation filed by Pfizer Inc., asserting that Pfizer is attempting to lower the acquisition price through litigation. Metsera's Board of Directors is committed to standing firm on behalf of shareholders. The litigation could impact the proposed acquisition by Pfizer and the market price of Metsera's common stock.